ASAM Makes Naloxone Recommendations to FDA

ASAM pic

Dr. Carol Lynn Childers serves as a consulting psychiatrist at Trilogy Behavioral Healthcare in Chicago. Alongside her work, Dr. Carol Lynn Childers maintains membership in the American Society of Addiction Medicine (ASAM).

In December 2018, ASAM contacted the Food and Drug Administration with its input on committee meetings of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee, specifically on issues related to naloxone availability. In its comments, the organization leaned upon many pillars of its official position statement, issued in 2016, which tout naloxone as a safe, effective intervention for opioid-related overdoses.

Suggestions ASAM put forward to the committees include prescribing naloxone if doctors feel a situation exists that exhibits risk factors associated with overdosing. ASAM also felt doctors should educate patients about the dangers of overdosing and how to correctly use naloxone in the event of an overdose. In addition, ASAM called for an over-the-counter solution for individuals who live in rural communities or other areas in which obtaining a prescription for the medication might be prohibitive.